Effect of recombinant human thyroid‐stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. (4th June 2015)

• Record Type: Journal Article
• Authors: Iakovou, Ioannis; Goulis, Dimitrios G.; Tsinaslanidou, Zinovia; Giannoula, Evanthia; Katsikaki, Grammatiki; Konstantinidis, Iordanis
• Is Part Of: Head & neck. Volume 38(2016)Supplement 1
• Page Start: E227
• Page End: E230
• Publication Date: 2015-06-04
• Subjects: sialadenitis -- 131‐iodine ablation -- thyroid cancer -- recombinant human thyroid‐stimulating hormone -- levothyroxine withdrawal; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23974
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The purpose of this study was to examine the incidence of sialadenitis and xerostomia within a year after radioactive iodine administration for thyroid remnant ablation after preparation with recombinant human thyroid‐stimulating hormone (rhTSH) or levothyroxine (LT4 ) withdrawal. Methods: The study has included 121 patients, divided into 4 groups: group A (rhTSH = 100 mCi), group B (rhTSH = 70 mCi), group C (LT4 withdrawal = 100 mCi), and group D (LT4 withdrawal = 70 mCi). Study outcomes were Summated Xerostomia Inventory score and number of sialadenitis episodes after radioactive iodine administration. Results: Salivary gland dysfunction was reported in 31% and 12% of patients, at the end of months 1 and 12, respectively. There was significantly lower incidence in groups A and B in comparison with groups C and D ( p = .002 and .021, respectively). Conclusion: The use of rhTSH for preparation of radioactive iodine ablation as opposed to LT4 withdrawal reduces the incidence of salivary gland dysfunction. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E227–E230, 2016